Cognitive reserve in Parkinson's disease without dementia: β-amyloid and metabolic assessment.
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
revised:
14
11
2023
received:
31
01
2023
accepted:
09
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
Cognitive reserve (CR) is the mismatch between preserved cognition and neuropathological damage. Amyloidopathy in Parkinson's disease (PD) could be associated with faster progression to dementia, but the putative protective effect of CR is unknown. To evaluate the effect of CR on β-amyloid burden and brain metabolism in non-demented PD subjects. Participants with PD (n= 53) underwent a clinical evaluation, [18F]-Fluorodeoxyglucose and [18F]-Flutemetamol PET-MRs, and were classified according to CR. The metabolic pattern of 16 controls was compared to PD subjects'. The PD subjects showed hypometabolism mainly in the bilateral posterior cortex. Superior-CR subjects (n= 22) exhibited better cognitive performance, increased amyloid burden, and higher metabolism in several right hemisphere areas compared to low-medium-CR subjects (n= 31). Higher CR in non-demented PD is associated with better cognitive performance, which might reduce vulnerability to the effect of β-amyloid. Whether superior CR leads to protection against metabolic deterioration, and predominantly right hemisphere involvement, deserves further exploration This article is protected by copyright. All rights reserved.
Sections du résumé
BACKGROUND
BACKGROUND
Cognitive reserve (CR) is the mismatch between preserved cognition and neuropathological damage. Amyloidopathy in Parkinson's disease (PD) could be associated with faster progression to dementia, but the putative protective effect of CR is unknown.
OBJECTIVES
OBJECTIVE
To evaluate the effect of CR on β-amyloid burden and brain metabolism in non-demented PD subjects.
METHODS
METHODS
Participants with PD (n= 53) underwent a clinical evaluation, [18F]-Fluorodeoxyglucose and [18F]-Flutemetamol PET-MRs, and were classified according to CR. The metabolic pattern of 16 controls was compared to PD subjects'.
RESULTS
RESULTS
The PD subjects showed hypometabolism mainly in the bilateral posterior cortex. Superior-CR subjects (n= 22) exhibited better cognitive performance, increased amyloid burden, and higher metabolism in several right hemisphere areas compared to low-medium-CR subjects (n= 31).
CONCLUSIONS
CONCLUSIONS
Higher CR in non-demented PD is associated with better cognitive performance, which might reduce vulnerability to the effect of β-amyloid. Whether superior CR leads to protection against metabolic deterioration, and predominantly right hemisphere involvement, deserves further exploration This article is protected by copyright. All rights reserved.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
This article is protected by copyright. All rights reserved.